Company / Cash & Equivalents
HARROW, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$72.9M
FY2025
5-year range
$42.2M / $96.3M
FY2021-FY2025
Trend
+54.4%
vs FY2024
Sector context
#164 of 207
Health Care
What the data says
HARROW, INC.'s cash & equivalents of $73M is lower than 79% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $73M.
Based on SEC 10-K filings.
$73M in FY2025 with a 5-year CAGR of +77.8%.
Remained stable around $73M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -8.8%
- 5-Year CAGR
- +77.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 207This company $72.9M Sector average $669.5M
▼
-89.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +77.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 54.4% year-over-year.
- Ranks #164 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.86 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $72.9M | +54.4% |
| FY2024 | $47.2M | -36.2% |
| FY2023 | $74.1M | -23.0% |
| FY2022 | $96.3M | +128.3% |
| FY2021 | $42.2M | +928.2% |
| FY2020 | $4.1M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $4.0M | +49.7% |
| FY2016 | $2.7M | -67.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026